GLP-1 agonists and SGLT2 inhibitors may primarily benefit individuals with glucose irregularities, and their effect in perfectly optimized individuals is uncertain.

“I I just I we don't have data in healthy people that much with SGLT2 and and GLP1. I mean, so mechanism of action is what? If these, if the GLP-1 group and the SGLT2 group are metabolically healthy, they don't have glucose excursions that are high, they're, you know, they're insulin. What is, what do you believe is the mechanism of action? I guess, you know, if it I think I I guess I'm going by a different statement, which is most people we're calling healthy are not totally metabolically healthy.”